The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade.

Permalink
https://escholarship.org/uc/item/3s21s4wt

Journal
European heart journal, 41(23)

ISSN
0195-668X

Authors
Kalla, Manish
Hao, Guoliang
Tapoulal, Nidi
et al.

Publication Date
2020-06-01

DOI
10.1093/eurheartj/ehz852

Peer reviewed
The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade

Manish Kalla1,2, Guoliang Hao1, Nidi Tapoulal1, Jakub Tomek1, Kun Liu1, Lavinia Woodward1, ‘Oxford Acute Myocardial Infarction (OxAMI) Study’, Erica Dall’Armellina 2, Adrian P. Banning2, Robin P. Choudhury2,3, Stefan Neubauer2, Rajesh K. Kharbanda2, Keith M. Channon 2, Olujimi A. Ajijola4, Kalyanam Shivkumar 4, David J. Paterson 1, and Neil Herring 1,2*

1Department of Physiology, Anatomy and Genetics, Burdon Sanderson Cardiac Science Centre, University of Oxford, Parks Road, Oxford OX13PT, UK; 2Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK; 3Radcliffe Department of Medicine, Acute Vascular Imaging Centre, University of Oxford, Oxford OX3 9DU, UK; and 4UCLA Cardiac Arrhythmia Center and Neurocardiology Research Center, Los Angeles, CA, USA

Received 12 June 2019; revised 29 August 2019; editorial decision 12 November 2019; accepted 12 November 2019; online publish-ahead-of-print 13 December 2019

Aims

ST-elevation myocardial infarction is associated with high levels of cardiac sympathetic drive and release of the co-transmitter neuropeptide Y (NPY). We hypothesized that despite beta-blockade, NPY promotes arrhythmogenesis via ventricular myocyte receptors.

Methods and results

In 78 patients treated with primary percutaneous coronary intervention, sustained ventricular tachycardia (VT) or fibrillation (VF) occurred in 6 (7.7%) within 48 h. These patients had significantly (P < 0.05) higher venous NPY levels despite the absence of classical risk factors including late presentation, larger infarct size, and beta-blocker usage. Receiver operating curve identified an NPY threshold of 27.3 pg/mL with a sensitivity of 0.83 and a specificity of 0.71. RT-qPCR demonstrated the presence of NPY mRNA in both human and rat stellate ganglia. In the isolated Langendorff perfused rat heart, prolonged (10 Hz, 2 min) stimulation of the stellate ganglia caused significant NPY release. Despite maximal beta-blockade with metoprolol (10 μmol/L), optical mapping of ventricular voltage and calcium (using RH237 and Rhod2) demonstrated an increase in magnitude and shortening in duration of the calcium transient and a significant lowering of ventricular fibrillation threshold. These effects were prevented by the Y1 receptor antagonist BIBO3304 (1 μmol/L). Neuropeptide Y (250 nmol/L) significantly increased the incidence of VT/VF (60% vs. 10%) during experimental ST-elevation ischaemia and reperfusion compared to control, and this could also be prevented by BIBO3304.

Conclusions

The co-transmitter NPY is released during sympathetic stimulation and acts as a novel arrhythmic trigger. Drugs inhibiting the Y1 receptor work synergistically with beta-blockade as a new anti-arrhythmic therapy.

Keywords

Neuropeptide Y • Myocardial infarction • Percutaneous coronary intervention • Ventricular tachycardia • Ventricular fibrillation
**Introduction**

Acute myocardial infarction (MI) is associated with high levels of cardiac sympathetic drive, which is a strong prognostic indicator for adverse outcomes and can trigger life-threatening ventricular arrhythmias. Despite significant improvements in mortality with emergency reperfusion and modern pharmacological treatment, large ST-elevation myocardial infarction (STEMI) is complicated by ventricular arrhythmias in up to 10% of cases. Indeed, the only primary prevention anti-arrhythmic drugs that reduce mortality following acute MI are beta-blockers. Prolonged cardiac sympathetic stimulation or experimentally induced MI in animal models also causes the release of non-catecholaminergic co-transmitters such as neuropeptide Y (NPY). We have shown that both local cardiac and circulating levels of the NPY are significantly elevated in patients with intact stellate ganglia and sympathetic innervation, and explore NPY released during sympathetic stimulation can promote ventricular arrhythmias in up to 10% of cases. Indeed, the only primary prevention anti-arrhythmic drugs that reduce mortality following acute MI are beta-blockers. We therefore hypothesized that despite maximal beta-blockade, NPY released during sympathetic stimulation can promote ventricular arrhythmias in a novel Langendorff perfused rat heart preparation with intact stellate ganglia and sympathetic innervation, and explore the underlying mechanisms. We also sought to ascertain whether patients undergoing PCI for STEMI with high plasma NPY levels were therefore more likely to experience ventricular arrhythmias. To further investigate possible causation, we tested whether NPY promotes arrhythmias during experimental ST-elevation ischaemia/reperfusion in the rat and explored the receptor pathways involved to assess whether these may be applicable for human pharmacological intervention.

**Methods**

See Supplementary material online for expanded methods. Patients with left coronary artery STEMI were recruited as part of the Oxford Acute Myocardial Infarction (OxAMI) study, which was approved by local ethics committee (REC: 10/H0408/24). All participants gave written informed consent. Stellate ganglia were collected from organ donors at the time of organ procurement as approved by the UCLA IRB and written informed consent was provided by the patient or appropriate designee. These studies comply with the Declaration of Helsinki. Animal use complied with the University of Oxford local ethical guidelines and was in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 2011) and the Animals (Scientific Procedures) Act 1986 (UK).

**Results**

Neuropeptide Y levels and ventricular arrhythmias in ST-elevation myocardial infarction patients following primary percutaneous coronary intervention

A total of 78 patients with acute left coronary artery STEMI (presenting throughout the 24 h cycle of clinical activity) were recruited and underwent peripheral venous blood sampling at the time of PCI. Overall patients were 63 ± 12.4 years old and 61/78 (78.2%) were male. The mean pain to balloon time was 218 ± 159 min. Peripheral venous NPY concentration was 19.0 [11.7–31.7] pg/mL. For comparison, the venous NPY level measured during elective coronary angiography in 12 patients of a similar age and sex, with similar cardiovascular risk factors but with unobstructed coronary arteries was 7.8 [6.5–12.2] pg/mL (see Table 1).

Sustained VT/VF was observed in 7.7% (6/78) of the STEMI patients. The individual characteristics of these patients in terms of pain to balloon time, arrhythmia timing, and termination are detailed in Supplementary material online, Table S1. Known clinical risk factors for ischaemia reperfusion arrhythmias following STEMI include cardiogenic shock, late presentation, larger infarct size, and prior beta-blocker usage. No patients in cardiogenic shock were included in our study, and patients with VT/VF in our cohort had a significantly faster pain to balloon time compared to the rest of the cohort, and a similar proportion had previous MIs and prior beta-blocker use (as shown in Table 2). Ejection fraction, oedema, and late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (MRI) at 48 h were also similar. However, patients with VT/VF had significantly higher venous plasma NPY levels compared to the rest of the study group (31.9 [27.8–47.7] vs. 17.8 [10.6–30.2] pg/mL).

The NPY levels of patients experiencing sustained VT/VF in relation to the entire NPY distribution are illustrated in Figure 1A. A receiver operating characteristic curve was used to define an NPY threshold that best identifies those patients with sustained VT/VF as shown in Figure 1B. A threshold NPY level of 27.3 pg/mL has a sensitivity of 0.83 and a specificity of 0.71 (area under the receiver operating characteristic curve: 0.77, 95% confidence intervals 0.65–0.90). The baseline characteristics of STEMI patients according to this...
threshold level are summarized in Table 3. Patients with high venous NPY levels were on average slightly older and a higher proportion were hypertensive. Usage of beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and statins prior to presentation were similar in the two groups and both groups had similar pain to balloon times, left anterior descending artery infarctions, flow-limiting bystander disease, and haemodynamic parameters. There was no association between beta-blocker dose on admission (equivalent...
Neuropeptide Y release and effects of ventricular electrophysiology and calcium handling

Using quantitative reverse transcription polymerase chain reaction (RT-qPCR) NPY mRNA was identified in human (n = 4) and rat (n = 4) stellate ganglia tissue (Figure 2A). Prolonged (2 min) high frequency (10 Hz) stimulation of either left or right stellate ganglia in the integrated sympathetic nerve rat heart model resulted in the release of NPY in the coronary perfusate (Figure 2B), although release of NPY was greater with left stellate stimulation (n = 6) compared to right (n = 6). Stimulation of either stellate ganglia also resulted in a frequency-dependent increase in heart rate and left ventricular developed pressure, greater with left (n = 5) compared to right (n = 7) stellate stimulation, which could be abolished with the beta-blocker metoprolol (10 μmol/L, Figure 2C and D) even during prolonged (2 min) high frequency (10 Hz) stimulation (right stellate: 261 ± 16 b.p.m. to 269 ± 16 b.p.m., 51 ± 8 mmHg to 56 ± 11 mmHg, left stellate: 252 ± 25 b.p.m. to 257 ± 25 b.p.m., 65 ± 16 mmHg to 71 ± 18 mmHg).

Optical mapping of voltage and intracellular calcium transients (using RH237 and Rhod2) at the anterior ventricular wall demonstrated that independent of heart rate (pacing at a cycle length of 140 ms), prolonged high-frequency stellate stimulation in the presence of metoprolol did not significantly change action potential duration (APD, 83 ± 21% n = 5) or activation time as shown in Figure 3A-C. However, there was a significant increase in the amplitude of the intracellular calcium transient accompanied by a significant shortening of the calcium transient duration as demonstrated in Figure 3D and E. The increase in calcium transient amplitude and shortening of the calcium transient duration could be prevented by a NPY Y1 receptor antagonist BIBO3304 (1 μmol/L, n = 5, Figure 3F and G).

Neuropeptide Y and ventricular fibrillation threshold in the isolated heart

To determine whether the increase in the magnitude and shortening in duration of the calcium transient predisposed the heart to ventricular arrhythmias, we measured ventricular fibrillation threshold (VFT) in response to burst pacing before and after prolonged high-frequency stellate ganglia stimulation in the presence of metoprolol. Right (n = 6) or left (n = 7) stellate stimulation in the presence of beta-blockade remained pro-arrhythmic with a significant reduction in VFT (Figure 4A and B) and this could be prevented by the addition of the Y1 receptor antagonist BIBO3304 (1 μmol/L, right n = 7, left n = 8) in combination with metoprolol (Figure 4C and D). This suggests that the pro-arrhythmic effect seen following prolonged high-frequency stellate ganglia stimulation in the presence of beta-blockade was due to NPY.

To further validate effective blockade of adrenergic receptor signalling, we demonstrated that metoprolol abolished the inotropic (control 70 ± 6 mmHg, norepinephrine 121 ± 18 mmHg; metoprolol and norepinephrine 63 ± 16 mmHg) and chronotropic response (control 247 ± 18 b.p.m., norepinephrine 296 ± 5 b.p.m., metoprolol and norepinephrine 246 ± 18 b.p.m.) to a maximal dose of norepinephrine (1 μmol/L) and also reversed a fall in VFT (n = 4) as shown in Figure 5A. Furthermore, metoprolol alone did not have a direct effect on VFT compared to control (n = 7) (Figure 5B). We also demonstrated that combined beta and alpha-receptor blockade (with propranolol, 1 μmol/L, and phentolamine, 1 μmol/L) also did not prevent the reduction in VFT to prolonged high-frequency stellate ganglia stimulation (n = 7) as shown in Figure 5C.

Neuropeptide Y and experimental induced ST-elevation ischaemia reperfusion arrhythmias

To directly assess whether NPY triggers ventricular arrhythmia, we assessed the incidence and severity of arrhythmia in the rat in the...
setting of ST-elevation ischaemia reperfusion. NPY \((n = 10)\) significantly increased the incidence of sustained VT and VF (60% vs. 10%) compared to control \((n = 10)\) and this could be abolished with the \(Y_1\) receptor antagonists BIBO3304 \((n = 10)\) as shown in Table 5.

**Discussion**

We report a novel mechanism by which sympathetic stimulation exerts a pro-arrhythmic effect on the ventricle. In the isolated heart,
prolonged high frequency stimulation of the stellate ganglia releases NPY which acts via the Y₁ receptor to increase the amplitude and shorten the duration of the ventricular myocyte calcium transient and lower ventricular fibrillation threshold, even in the presence of maximal beta-blockade (see Take home figure). Importantly, combining beta-blockade with a Y₁ receptor antagonist abolishes the pro-arhythmic effect of stellate ganglia stimulation. In patients presenting with STEMI treated with PPCI, NPY levels are associated with an increased incidence of ventricular arrhythmia in the immediate post-infarct period independent of classical risk factors such as late presentation, larger infarct size, and prior beta-blocker usage. Moreover, NPY also increases the incidence of ventricular arrhythmias during experimental ST-elevation ischaemia reperfusion and this can also be prevented by a Y₁ receptor antagonist.

Neuropeptide Y has a variety of effects on the cardiovascular system including acutely causing vasoconstriction, reducing acetylcholine release from the cardiac vagus and subsequent bradycardia, as well as promoting ventricular and vascular remodelling in the long term. It may also be involved in the pathogenesis of atherosclerosis. Here, we assess the acute effects of NPY release on ventricular electrophysiology, calcium handling, and arrhythmogenesis at the whole organ level and mitigate the effects of vasoconstriction by utilizing a constant flow system ensuring stable delivery of oxygen and metabolic substrate. Our isolated innervated heart preparation represents a useful model for the study of sympathetic control of arrhythmia.

### Table 3  Clinical characteristics according to venous NPY threshold

| STEMI patients | Low NPY (n = 52) | High NPY (n = 26) | P-value |
|----------------|-----------------|-----------------|---------|
| Age            | 60.6 ± 12.7     | 67.9 ± 10.4     | 0.01    |
| Males          | 42/52 (80.8%)   | 19/26 (73.1%)   | 0.62    |
| Cardiovascular risk factors |                  |                 |         |
| Hypertension   | 19/52 (36.5%)   | 17/26 (66.4%)   | 0.03    |
| Hyperlipidaemia| 17/52 (32.7%)   | 15/26 (57.7%)   | 0.06    |
| Diabetes mellitus| 5/52 (9.6%)   | 5/26 (19.2%)    | 0.29    |
| Current/Ex-smoker | 42/52 (80.8%) | 19/26 (73.1%) | 0.62    |
| Family history | 16/52 (30.8%)   | 10/26 (38.5%)   | 0.67    |
| Previous MI     | 3/52 (5.8%)     | 4/26 (15.4%)    | 0.21    |
| Medications on admission |              |                 |         |
| Beta-blockers   | 7/52 (13.5%)    | 5/26 (19.2%)    | 0.74    |
| ACE inhibitor/ATR antagonist | 9/52 (17.3%) | 9/26 (34.6%) | 0.15    |
| Statin         | 10/52 (19.2%)   | 8/26 (30.8%)    | 0.39    |
| BP and heart rate at presentation |            |                 |         |
| Systolic BP (mmHg) | 133.8 ± 24.5  | 135.8 ± 27.2   | 0.75    |
| Diastolic BP (mmHg) | 82.1 ± 15.7   | 77.2 ± 18.6    | 0.25    |
| Heart rate (l/min) | 80.4 ± 20.9    | 78.4 ± 22.0    | 0.71    |
| Pain to balloon time (min) | 233 ± 162   | 189 ± 129      | 0.21    |
| LAD infarct     | 37/52 (71.2%)   | 21/26 (80.8%)   | 0.52    |
| Flow-limiting bystander disease | 5/52 (9.6%) | 5/26 (19.2%) | 0.40    |
| Cardiac MRI     |                |                 |         |
| Ejection fraction (%) | 47 ± 9      | 43 ± 10        | 0.14    |
| LGE (%)         | 32 ± 14        | 32 ± 19        | 0.95    |
| Oedema (%)      | 44 ± 16        | 45 ± 15        | 0.83    |
| Venous NPY concentration (pg/mL) | 13.9 [9.2–18.8] | 45.2 [31.7–78.9] | <0.0001 |

Values are mean ± standard deviation, n (%), median [interquartile range].

ACE, angiotensin converting enzyme; ATR, angiotensin receptor; BP, blood pressure; LAD, left anterior descending; LGE, late gadolinium enhancement; MI, myocardial infarction; MRI, magnetic resonance imaging; STEMI, ST-elevation myocardial infarction.

### Table 4  Ventricular arrhythmias according to venous NPY threshold

| Arrhythmia | STEMI arrhythmia frequency |
|------------|----------------------------|
|            | Low NPY (n = 52) | High NPY (n = 26) |
| None       | 35/52 (67.3%) | 12/26 (46.2%) |
| VEs        | 11/52 (21.2%) | 8/26 (30.8%) |
| NSVT       | 5/52 (9.6%)  | 1/26 (3.8%)  |
| VT         | 1/52 (1.9%)  | 3/26 (11.5%) |
| VF         | 0            | 2/26 (7.7%)  |

NSVT, non-sustained ventricular tachycardia; STEMI, ST-elevation myocardial infarction; VEs, ventricular ectopic beats; VF, ventricular fibrillation; VT, sustained ventricular tachycardia.

P = 0.01 for VT/VF between experimental groups.

NPY and ventricular arrhythmias during myocardial infarction 2173
Other isolated heart models to date have employed spinal cord stimulation to produce efferent post-ganglionic sympathetic nerve stimulation although retrograde stimulation of afferent fibres, or activation of local reflexes may confound observations. Using our model, we clearly demonstrate that stimulation of the stellate ganglia leads to NPY release during prolonged high frequency stimulation and that whilst metoprolol was able to block the physiological effects of endogenous released and exogenous norepinephrine on heart rate and left ventricular developed pressure, it was unable to prevent an increase in the amplitude and shortening of duration of the intracellular calcium transient and reduction in VFT. This is suggestive of an additional substance being released during sympathetic stimulation that

Figure 3 The effects of neuropeptide Y on ventricular calcium handling and voltage. (A) Schematic diagram showing the area of optical mapping and raw data trace showing the effects of prolonged high frequency (10 Hz, 2 min) bilateral stellate ganglia stimulation on both calcium and voltage. (B and C) Group mean data showing the effects of bilateral stellate ganglia in the presence of beta-blockade (n = 5) and (D and E), in the presence of beta-blockade and Y₁ receptor antagonism with BIBO3304 (1 μmol/L, n = 5).
may have a pro-arrhythmic effect. Exogenous NPY can also act as an independent arrhythmic trigger during ST-elevation ischaemia reperfusion and, consistent with these observations, a combination of metoprolol and Y<sub>1</sub> receptor blockade prevents the changes in intracellular calcium handling and decrease in VFT during stellate ganglia stimulation, or the triggered arrhythmias during ST-elevation ischaemia/reperfusion.

Although no animal model has identical electrophysiology and expresses the same combination of co-transmitters compared to human, the rat remains the best-studied model of NPY action at the single ventricular myocyte level in terms of electrophysiology and calcium handling, and NPY is the dominant sympathetic co-transmitter<sup>16</sup> rather than galanin as seen in the mouse<sup>17</sup> and guinea pig<sup>6</sup>. Our data confirm NPY mRNA in both human and rat stellate ganglia which have also been demonstrated by immunohistochemistry in the former.<sup>18</sup> Consistent with our findings in the whole heart, studies on isolated ventricular myocytes in the rat have demonstrated that NPY increases the magnitude of the intracellular calcium transient and causes diastolic calcium release events potentially due to coupling of NPY receptors to a phospholipase C, IP<sub>3</sub> dependent pathway.<sup>11</sup>

Existing data on ion channel effects of NPY in isolated cardiomyocytes are variable. No alteration in sodium current (I<sub>Na</sub>) or delayed rectifier potassium current (I<sub>Kr</sub>) activity have been demonstrated<sup>19</sup> but I<sub>Na</sub> was reduced.<sup>15</sup> The effects on I<sub>Ca</sub> have been shown to be species dependent with inhibition in guinea pig<sup>13</sup> and stimulation in rat cardiac myocytes.<sup>20</sup> However, we observe no overall effect of NPY on APD or activation times at fixed rate pacing in our model.

The pathophysiology of ventricular arrhythmias following ischaemia and reperfusion is complex. Ischaemia causes a reduction in cellular adenosine triphosphate (ATP), raises extracellular potassium through opening of ATP sensitive potassium channels, reduces inward rectifier potassium current (I<sub>Kr</sub>) and the activity of the Na<sup>+</sup>/K<sup>+</sup> ATPase. It also causes localized acidosis, uncoupling of gap junctions, and the generation of reactive oxygen species.<sup>21</sup> There is an overall shortening of APD and refractory period as well as reduction in conduction velocity which predisposes to re-entrant arrhythmias. On reperfusion, acid extrusion via Na<sup>+</sup>/H<sup>+</sup> exchange leads to a rise in intracellular Na<sup>+</sup> and subsequently Ca<sup>2+</sup> via NCX<sup>22</sup>. Phosphorylation of calcium handling proteins by calcium-calmodulin dependent protein kinase II (CaMKII),<sup>23</sup> and cellular calcium overload can lead to spontaneous sarcoplasmic reticulum calcium release, delayed afterdepolarization and initiate arrhythmias, whilst the spatial heterogeneity in repolarization, together with oedema and scar formation can also facilitate re-entry.<sup>14,21,23</sup> All of these processes are exacerbated by sympathetic stimulation via the beta-adrenergic receptor, but even in the presence of beta-blockade, facilitation of sarcolemmal and subsequent dyssynchronous calcium release by NPY signalling would be a potent pro-arrhythmic trigger.

The role of NPY as a non-adrenergic, sympathetic neuron derived pro-arrhythmic co-transmitter is supported by our observations in the OxAMI cohort of patients undergoing PPCI for STEMI. Direct stimulation of the cardiac sympathetic innervation leads to the appearance of NPY in coronary sinus (CS) blood<sup>24</sup> and we have shown that during STEMI CS and peripheral venous NPY levels are strongly correlated.<sup>8</sup> Neuropeptide Y also has a long plasma half-life, and we have previously demonstrated that despite revascularization peripheral venous NPY levels remain significantly elevated for at least 48 h after treatment.<sup>7</sup> In the OxAMI cohort, we therefore measured peripheral venous NPY levels immediately following PPCI and recorded ventricular arrhythmias during the first 48 h after reperfusion when 90% are known to occur. However, despite the lack of classical risk factors for ischaemia–reperfusion ventricular arrhythmias such as cardiogenic shock, late-presentation, larger infarct size, prior beta-blocker use, or longer pain to balloon time, patients with sustained VT/VF had significantly higher NPY levels. Interestingly, patients with high levels of NPY as defined by the receiver operating characteristic curve were more likely to be hypertensive, and recent data have also implicated NPY in the pathogenesis of hypertension.<sup>25</sup>

Historical studies undertaken in the 1980s before the advent of PPCI and modern medical treatment have shown that venous ‘NPY-like activity’ is elevated during ischaemic events and left ventricular failure and correlates with 1-year mortality.<sup>26,27</sup> Unlike these early studies our assay is highly sensitive (2–3 pg/mL compared to >90 pg/mL) and selective (0% cross-reactivity with structurally similar peptides such as PYY, PP, GIP, ghrelin, proinsulin, or glucagon). We observe peripheral venous levels of NPY around three times that of

---

**Figure 4** The effects of neuropeptide Y on ventricular fibrillation threshold. (A and B) The effects of prolonged high frequency (10 Hz, 2 min) right stellate ganglia (n = 6) or left stellate ganglia (n = 7) stimulation in the presence of beta-blockade with metoprolol (10 μmol/L) on ventricular fibrillation threshold assessed by burst pacing. (C and D) Group mean data showing the effects of right stellate ganglia (n = 7) or left stellate ganglia (n = 8) stimulation in the presence of beta-blockade and Y<sub>1</sub> receptor antagonism with BIBO3304 (1 μmol/L).
Figure 5  Effective adrenergic receptor blockade. (A) Beta-blockade with metoprolol (10 μmol/L) reverses the fall in ventricular fibrillation threshold in response to a maximal dose of norepinephrine (1 μmol/L, n = 4). (B) Beta-blockade does not influence ventricular fibrillation threshold compared to control (n = 7). (C) Combined beta and alpha-blockade (with propranolol, 1 μmol/L, and phentolamine, 1 μmol/L, P+P) does not prevent the fall in ventricular fibrillation threshold in response to prolonged high frequency (10 Hz, 2 min) left stellate ganglia stimulation (n = 7).

Table 5  NPY and ventricular reperfusion arrhythmias following experimental ST-elevation ischaemia

| ECG example | Arrhythmia | Control | NPY | NPY + BIBO |
|-------------|------------|---------|-----|-----------|
| None        | 8/10       | 1/10    | 1/10|           |
| VEs         | 1/10       | 3/10    | 9/10|           |
| VT          | 1/10       | 1/10    | 0   |           |
| VF          | 0          | 5/10    | 0   |           |

P = 0.006 for VT/VF between experimental groups. ECG, electrocardiogram.
patients undergoing elective coronary angiography with normal coronary arteries (7.8 pg/mL). Others have measured similarly low levels of venous NPY in healthy adults around 2 pg/mL. Using the same assay, we have also recently shown in patients with severe heart failure undergoing implantation of cardiac resynchronization therapy devices, that coronary sinus levels of NPY are significantly higher than in the STEMI population and are strongly associated with mortality.

Limitations

Ventricular arrhythmias causing out of hospital cardiac arrests have very low survival to discharge rates that are dependent on bystander recognition, adequate cardiopulmonary resuscitation, and early defibrillation. Such arrhythmias are clinically more serious than those witnessed peri-PPCI, although all sustained ventricular arrhythmias are potentially life-threatening. Sustained VT and VF occurring immediately pre- and post-PPCI are associated with higher rates of early and in-hospital mortality. It is challenging to thoroughly phenotype patients with out of hospital cardiac arrests prior to the arrest itself. These patients are often intubated prior to PPCI and therefore unable to consent, and frequently suffer from cardiogenic shock (an exclusion criteria in our study). Measuring NPY after such events is also complicated by the fact that the arrest itself will significantly raise sympathetic drive and NPY levels making it difficult to ascertain whether NPY played any role in their initiation. It would have been interesting to see whether the release profile of NPY throughout the 48 h of monitoring provides any additional prognostic information regarding late ventricular arrhythmia occurrence, but given that 90% of ventricular arrhythmias occur within the first 48 h, a far larger study would be required to address this question. We also do not have 12-lead electrocardiograms (ECGs) of all the observed arrhythmias in order to localize an electrocardiographic origin, as arrhythmias were mostly captured by standard ECG Holter monitoring and/or the rhythm strips from a defibrillator.

Whilst constant frequency stimulation is used universally for experimental neural stimulation, this clearly does not reproduce spontaneous neuronal firing observed in vivo. However, our stimulation parameters produce physiological changes in heart rate and left ventricular developed pressure and increased NPY levels as observed in the STEMI population. Inducing ventricular arrhythmias through pacing protocols could also be considered unphysiological, and the same criticism can also be applied to clinical VT stimulation testing (e.g., using the Wellens protocol). Ventricular fibrillation threshold testing in animal models allows for paired measurements of susceptibility before and after complex multi-step experimental interventions and therefore remains useful. However, we were careful to also demonstrate the effects of NPY on reperfusion arrhythmias induced by experimental ST-elevation ischaemia reperfusion in the rat as proof of principle that our findings are applicable to arrhythmogenesis following PPCI for STEMI.

Clinical implications

Despite over half a century of research, the only primary prevention anti-arrhythmic drugs that reduce mortality following acute MI are beta-blockers. There is therefore an urgent need to identify new therapeutic targets and our data support the notion that blockers of
the Y1 receptor may offer a novel pharmacological strategy in patients with ventricular arrhythmias, working synergistically with beta-blockers, and other secondary prevention medications. There is the possibility of administering such drugs via an intracoronary route at the time of PCI, given their potential to also improve microvascular resistance and reduce infarct size, and/or via infusions during the first 48 h when NPY levels are at their highest, although the best approach is yet to be established.

It is also interesting to note that a variety of interventions aimed at reducing cardiac sympathetic drives such as cardiac sympathetic denervation, thoracic epidural anaesthesia, and renal denervation 2,3 have shown promise in treating recurrent VT in patients with severe heart failure and long-QT syndrome, despite being treated with maximal doses of beta-blockers and receiving recurrent implantable cardioverter-defibrillator therapies. It may be that their efficacy is partly due to reducing the pro-arrhythmic action of NPY release in addition to simply reducing the release of catecholamines.

**Supplementary material**

**Supplementary material** is available at European Heart Journal online.

**Acknowledgements**

This study would not have been possible without the tireless support of the coronary care unit and catheter laboratory staff of the Oxford Heart Centre at the John Radcliffe Hospital. The contributions of colleagues in the Oxford Acute Vascular Imaging Centre are also acknowledged. We are also very grateful to the patients who participated.

**Funding**

British Heart Foundation Intermediate Fellowship (FS/15/8/3115) and an Oxford Health Services Research grant (OHSRC: 1135) to N.H.; a BHF Clinical Research Fellowship to M.K.; National Institutes of Health (HL125730 and DP2HL142045 to O.A.A., HL084261 and OT2OD023848 to K.S.). N.H., M.K., K.C., and D.J.P. also acknowledge support from the BHF Centre of Research Excellence (RE/08/004), Oxford, and the Oxford National Institute for Health Research (NIHR) Biomedical Research Centre.

**Conflict of interest:** none declared.

**References**

1. Malliani A, Schwartz PJ, Zanchetti A. A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol 1969;217:703–709.

2. Herring N, Kalla M, Paterson DJ. The autonomic nervous system and cardiac arrhythmias: current concepts and emerging therapies. Nat Rev Cardiol 2019;16:760.

3. Schwartz PJ. Cardiac sympathetic denervation to prevent life-threatening arrhythmias. Nat Rev Cardiol 2014;11:346–353.

4. Ibarz B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudievens A, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valignighi M, Varesehorst C, Vranckx P, Widimsky P. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.

5. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57–66.

6. Herring N, Cranley J, Lokale MN, Li D, Shanks J, Alsten EN, Girard BM, Carter E, Parsons RL, Habeker BA, Paterson DJ. The cardiac sympathetic co- transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability. J Mol Cell Cardiol 2012;52:667–676.

7. Han CS, Wang XA, Fiscus RR, Gu J, McDonald JK. Changes in cardiac neuropeptide Y after experimental myocardial infarction in rat. Neurosci Lett 1989;104:141–146.

8. Herring N, Tapoulal N, Kalla M, Ye X, Borysova L, Lee R, Dell’Ammelina E, Stanley C, Ascione R, Lu C-J, Banning AP, Choudhry RP, Neubauer S, Dora K, Hcharbenda RK, Channon KM, Banning AP, Choudhry RP, Neubauer S, Dora K, Khambdka RK, Channom KM. Neuropeptide Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction. Eur Heart J 2019;40:1920–1929.

9. Cuculli F, Herring N, De Caterina AR, Banning AP, Prendergast BD, Forfar JC, Choudhry RP, Channon KM, Khambda RK. Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction. Heart 2013;99:1198–1203.

10. Tan CMJ, Green P, Tapoulal N, Lewandowski AJ, Leeson P, Herring N. The role of neuropeptide Y in cardiovascular health and disease. Front Physiol 2018;9:1281.

11. Heredia M, Delgado C, Pereira L, Perrier R, Richard S, Vassort G, Benitah J, Gomez A. Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. J Mol Cell Cardiol 2003;38:205–212.

12. Heredia MP, Fernandez-Velasco M, Benito G, Delgado C. Neuropeptide Y increases 4-aminoypyridine-sensitive transient outward potassium current in rat ventricular myocytes. Br J Pharmacol 2002;135:1701–1706.

13. Bryant SM, Hart G. Effects of neuropeptide Y on L-type calcium current in guinea-pig ventricular myocytes. Br J Pharmacol 1996;118:1453–1460.

14. Gorenek B, Blomstrom Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, Huber K, Kirchholz P, Kuck K-H, Kudabberdiera G, Lin T, Ravele A, Santini M, Titz RR, Valigimigli M, Vos MA, Vrints C, Zeyer M, Kristiansen SB, Lip GYH, Potpara T, Fauchier L, Sticherling C, Rolfi M, Widimsky P, Mehilii J, Lietto M, Schiele F, Sinaee P, Boriani G, Lane D, Savelieva I. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EUROHART, ACCA, and EAPCI task force. Europace 2014;16:1655–1673.

15. Herring N, Lokale MN, Danson EJ, Heaton DA, Paterson DJ. Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. J Mol Cell Cardiol 2008;44:477–485.

16. Smith-White MA, Wallace D, Porter EK. Sympathetic-parasympathetic interactions at the heart in the anesthetised rat. Auton Nerv Syst 1999;75:171–177.

17. Porter EK, Smith-White MA. Galanin modulates cholinergic neurotransmission in the heart. Neuropeptides 2005;39:345–348.

18. Ajioka OA, Yagishita D, Reddy NK, Yamakawa K, Vaseghi M, Downs AM, Hoover DB, Ardell JL, Shivikumr K. Remodeling of stellate ganglion neurons after spatially targeted myocardial infarction: neuropeptide and morphologic changes. Heart Rhythm 2015;12:1027–1035.

19. Zhao HC, Liu ZB, Feng QL, Cui XL, Zhang CM, Wu BW. [Effects of neuropeptide Y on ion channels in ventricular myocytes]. Sheng Li Xue Bao 2008;58:225–231.

20. Miliar BC, Weis T, Piper HM, Webster M, Borchard U, McDermott BJ, Balasubramaniam A. Positive and negative contractile effects of neuropeptide Y on ventricular cardiomyocytes. Am J Physiol 1991;261(6 Pt H):H1727–H1733.

21. Carmeliet E. Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol Rev 1999;79:917–1017.

22. Pogwizd SM, Schlottka K, Li L, Yuan W, Bers DM. Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 2001;88:1159–1167.

23. Bell JR, Erickson JR, Delbridge LM. Ca2+/calmodulin dependent kinase II: a critical mediator in determining reperfusion outcomes in the heart? Clin Exp Pharmacol Physiol 2014;41:940–946.

24. Warner MR, Senarayake PD, Ferrario CM, Levy MN. Sym pathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart. Circ Res 1991;69:455–465.

25. Shanks J, Manou-Stathopoulou S, Lu C-J, Li D, Paterson DJ, Herring N. Cardiac sympathetic dysfunction in the prehypertensive spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2013;305:H1890–H1896.

26. Ullman B, Hulting J, Lundberg JM. Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J 1994;15:454–461.

27. Hulting J, Salvei A, Ullman B, Franco-Cereceda A, Lundberg JM. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 1990;24:102–108.
An unusual coronary embolus in a patient with prosthetic endocarditis

Jessey Mathew1, Jeffrey B. Geske 2, Sushil Allen Luis 2, and Hartzell V. Schaff1

1Department of Cardiothoracic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; and 2Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

A 66-year-old woman presented with prosthetic valve endocarditis and native mitral valve endocarditis caused by Streptococcus mitis 3 years after an aortic valve (Edwards Lifesciences 23 mm Magna) and aortic root replacement for bicuspid valve at another institution. She denied any chest pain. Transoesophageal echocardiogram demonstrated destructive aortic prosthesis changes, severe periprosthetic regurgitation, and mobile native mitral valve vegetation. A computed tomography (CT) angiogram of the chest to evaluate for peri-aortic graft infection and preoperative coronary evaluation revealed a high-density, cylindrical, man-made object in the distal ramus intermedius, suspected to be a Cor-Knot from the aortic valve prosthesis (Panel A). The timing of embolization was unknown. The 3D reconstruction revealed absence of a Cor-Knot from the prosthesis (Panel B). The patient underwent aortic valve re-replacement and mitral valve repair with excision of vegetation from the anterior mitral leaflet. Further surgical exploration confirmed a missing Cor-Knot on the aortic valve prosthesis (Panel C) corresponding to the location noted on CT. The Cor-Knot was successfully removed from the ramus intermedius (Panels C and D). Post-operative recovery was uneventful.

Although Cor-Knot embolization to the coronary has not previously been reported, this case demonstrates that post-operative Cor-Knot embolization may occur and can be asymptomatic. The timing of embolization and role of concomitant infection are uncertain. Visualization of high-density emboli in patients with prior valve replacements should prompt consideration of Cor-Knot embolization as a potential source. In such instances, careful assessment of the valve prosthesis using multiplanar and 3D reconstruction can highlight deficiencies in Cor-Knot placement confirming the diagnosis.

The authors would like to thank Dr. Thomas Foley for his assistance in 3D reconstruction of the CT images.